Loading...
Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
BACKGROUND: Clinical trial results suggest that 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) may increase the risk of gynecomastia and male breast cancer, but epidemiological studies have been limited. PATIENTS AND METHODS: We conducted a cohort study...
Na minha lista:
| Udgivet i: | Clin Epidemiol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5312705/ https://ncbi.nlm.nih.gov/pubmed/28228662 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CLEP.S124674 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|